Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2006 1
2012 2
2019 1
2020 1021
2021 1414
2022 1070
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

3,179 results
Results by year
Filters applied: . Clear all
Page 1
Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
Sreekanth Reddy O, Lai WF. Sreekanth Reddy O, et al. Chembiochem. 2021 Mar 16;22(6):939-948. doi: 10.1002/cbic.202000595. Epub 2020 Nov 11. Chembiochem. 2021. PMID: 33031623 Free PMC article. Review.
This article provides an overview of the life cycle and routes of transmission of SARS-CoV-2. The therapeutic effects of two drugs [i. e., remdesivir (RDV) and favipiravir (FPV)] which can potentially tackle COVID-19 are discussed based on current published data. ...
This article provides an overview of the life cycle and routes of transmission of SARS-CoV-2. The therapeutic effects of two drugs [i. e., …
Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.
Jorgensen SCJ, Kebriaei R, Dresser LD. Jorgensen SCJ, et al. Pharmacotherapy. 2020 Jul;40(7):659-671. doi: 10.1002/phar.2429. Epub 2020 Jun 28. Pharmacotherapy. 2020. PMID: 32446287 Free PMC article. Review.
The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an urgent need for effective antivirals. Remdesivir (formerly GS-5734) is a nucleoside analogue pro-drug currently being eval …
The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has …
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial.
Rosas IO, Diaz G, Gottlieb RL, Lobo SM, Robinson P, Hunter BD, Cavalcante AW, Overcash JS, Hanania NA, Skarbnik A, Garcia-Diaz J, Gordeev I, Carratalà J, Gordon O, Graham E, Lewin-Koh N, Tsai L, Tuckwell K, Cao H, Brainard D, Olsson JK. Rosas IO, et al. Intensive Care Med. 2021 Nov;47(11):1258-1270. doi: 10.1007/s00134-021-06507-x. Epub 2021 Oct 5. Intensive Care Med. 2021. PMID: 34609549 Free PMC article. Clinical Trial.
Serious adverse events occurred in 128 (29.8%) tocilizumab plus remdesivir and 72 (33.8%) placebo plus remdesivir patients; 78 (18.2%) and 42 (19.7%) patients, respectively, died by day 28. CONCLUSIONS: Tocilizumab plus remdesivir did not shorten time to hosp …
Serious adverse events occurred in 128 (29.8%) tocilizumab plus remdesivir and 72 (33.8%) placebo plus remdesivir patients; 78 …
Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Malin JJ, et al. Clin Microbiol Rev. 2020 Oct 14;34(1):e00162-20. doi: 10.1128/CMR.00162-20. Print 2020 Dec 16. Clin Microbiol Rev. 2020. PMID: 33055231 Free PMC article. Review.
Patients and physicians worldwide are facing tremendous health care hazards that are caused by the ongoing severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) pandemic. Remdesivir (GS-5734) is the first approved treatment for severe coronavirus disease 20 …
Patients and physicians worldwide are facing tremendous health care hazards that are caused by the ongoing severe acute respiratory distress …
Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.
Gérard AO, Laurain A, Fresse A, Parassol N, Muzzone M, Rocher F, Esnault VLM, Drici MD. Gérard AO, et al. Clin Pharmacol Ther. 2021 Apr;109(4):1021-1024. doi: 10.1002/cpt.2145. Epub 2021 Jan 16. Clin Pharmacol Ther. 2021. PMID: 33340409
The combination of the terms "acute renal failure" and "remdesivir" yielded a statistically significant disproportionality signal with 138 observed cases instead of the 9 expected. ROR of ARF with remdesivir was 20-fold (20.3; confidence interval 0.95 [15.7-26.3], P …
The combination of the terms "acute renal failure" and "remdesivir" yielded a statistically significant disproportionality signal wit …
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Wang Y, et al. Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29. Lancet. 2020. PMID: 32423584 Free PMC article. Clinical Trial.
Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1.23 [95% CI 0.87-1.75]). ...Adverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. Remdesivir was stop
Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1.23 [95% CI 0.87-1.75]). ...Advers
A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
Simonis A, Theobald SJ, Fätkenheuer G, Rybniker J, Malin JJ. Simonis A, et al. EMBO Mol Med. 2021 Jan 11;13(1):e13105. doi: 10.15252/emmm.202013105. Epub 2020 Nov 3. EMBO Mol Med. 2021. PMID: 33015938 Free PMC article. Review.
By repurposing of broadly active antiviral drugs and compounds that are known to inhibit viral replication of related viruses, several advances could be made in the development of treatment strategies against COVID-19. The nucleoside analog remdesivir, which is known for i …
By repurposing of broadly active antiviral drugs and compounds that are known to inhibit viral replication of related viruses, several advan …
Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies.
Singh AK, Singh A, Singh R, Misra A. Singh AK, et al. Diabetes Metab Syndr. 2020 Jul-Aug;14(4):641-648. doi: 10.1016/j.dsx.2020.05.018. Epub 2020 May 12. Diabetes Metab Syndr. 2020. PMID: 32428865 Free PMC article. Review.
BACKGROUND & AIMS: Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In absence of any effective treatment for SARS-CoV-2 infection (COVID-19), remdesivir has been tried for a compassionate use in severe C …
BACKGROUND & AIMS: Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In …
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM; GS-US-540-5774 Investigators. Spinner CD, et al. JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349. JAMA. 2020. PMID: 32821939 Free PMC article. Clinical Trial.
Median length of treatment was 5 days for patients in the 5-day remdesivir group and 6 days for patients in the 10-day remdesivir group. ...By day 28, 9 patients had died: 2 (1%) in the 5-day remdesivir group, 3 (2%) in the 10-day remdesivir group, and …
Median length of treatment was 5 days for patients in the 5-day remdesivir group and 6 days for patients in the 10-day remdesivir
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Choy KT, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KPY, Chu DKW, Chan MCW, Cheung PP, Huang X, Peiris M, Yen HL. Choy KT, et al. Antiviral Res. 2020 Jun;178:104786. doi: 10.1016/j.antiviral.2020.104786. Epub 2020 Apr 3. Antiviral Res. 2020. PMID: 32251767 Free PMC article.
We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, h …
We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that …
3,179 results